Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor

• Published in: BMC cancer 2015-12, Vol.15 (962), p.957-957, Article 957
• Main Authors: Nishimura, Toshio, Nakamura, Kazuto, Yamashita, Soichi, Ikeda, Sadatomo, Kigure, Keiko, Minegishi, Takashi
• Format: Article
• Language: English
• Subjects: Animals; Antibodies; Antineoplastic Agents - pharmacology; Blotting, Western; Cancer therapies; Carcinoma, Endometrioid - genetics; Carcinoma, Endometrioid - pathology; Charcoal; Complications and side effects; Cytotoxicity; Drug therapy; Endometrial cancer; Endometrial Neoplasms - genetics; Endometrial Neoplasms - pathology; Epidermal growth factor; Erlotinib; Erlotinib Hydrochloride - pharmacology; Female; Health aspects; Humans; Immunohistochemistry; Kinases; Medical prognosis; Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Patients; Phenols; Proteins; Receptor, Epidermal Growth Factor - biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Risk factors; RNA, Small Interfering; Transfection; Tumors; Xenograft Model Antitumor Assays
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-015-1975-5

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, has been clinically applied for the treatment of a variety of tumors with EGFR overexpression. A phase II clinical study of erlotinib (NCIC IND-148) for recurrent or metastatic endometrial carcinoma (EC) resulted in an unfavorable result. However, in that study, the expression levels of EGFR were not accurately analyzed. Thus, the aim of this study was to re-examine the efficacy of erlotinib in EC cells by utilizing in vitro and in vivo models. Tissue samples obtained from patients histologically diagnosed with EC of the uterine corpus were subjected to immunohistochemistry and RT-PCR to determine the protein and mRNA expression levels of EGFR. Western blot and WST-1 assays of EGFR siRNA-transfected HEC-1A, KLE, and Ishikawa cells were used to evaluate the efficacy of erlotinib in tumor cell lines expressing different EGFR levels. Furthermore, HEC-1A and Ishikawa cells were implanted into athymic mice treated with either erlotinib or trastuzumab. At our institution, 20.9% of endometrial cancer patients with low grade endometrioid histology have been diagnosed as stage III and IV. Immunohistochemical analysis and RT-PCR revealed the presence of significant EGFR and EGFR mRNA expression in low-grade endometrioid carcinoma in comparison with high-grade endometrioid carcinoma. In vitro study, WST-1 assay and Western blot analysis revealed that EGFR expression levels were correlated with tumor cell viability. Erlotinib reduced the proliferation of HEC-1A expressing high levels of EGFR, while trastuzumab showed similar effect in Ishikawa cells dominantly expressing human epidermal growth factor receptor type2 (HER2). In vivo erlotinib decreased tumor growth in mice xenografted with HEC-1A cells, whereas this tumor-growth inhibition was not observed in trastuzumab-treated mice xenografted with Ishikawa cell. EGF contributed to tumor proliferation in EC cell lines along with EGFR expression in vitro. Erlotinib also demonstrated anti-tumor effects in xenograft mice models. Our results suggest that erlotinib continues to have clinical usefulness in specific cases, after taking into consideration the EGFR expression levels.